GENFIT is Filing for IND Submission for New Indication of Elafibranor in Primary Biliary Cholangitis (PBC)
Filing of Investigational New Drug (IND) application for a new indication of elafibranor in Primary Biliary Cholangitis (PBC), a rare disease with unmet need and only two orphan products approved to date
Launch of a Phase 2 study to evaluate the efficacy and safety of elafibranor in PBC adult patient population: 3 month treatment; 30 patients; evaluation of ALP decrease vs placebo; sites in both the United States and Europe
Lille (France), Cambridge (Massachusetts, United States), September 27, 2016 - GENFIT (Euronext: GNFT - ISIN: FR0004163111), a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that notably affect the liver or the gastrointestinal system, today announced that it is filing an IND submission for a Phase 2 trial in Primary Biliary Cholangitis (PBC), aimed at evaluating decrease in alkaline phosphatase (ALP) with elafibranor vs placebo.
This trial is designed to be a multicenter, double-blind, randomized, placebo-controlled, phase 2 study to evaluate the efficacy and safety of elafibranor after 12 weeks of treatment in patients with PBC and inadequate response to ursodeoxycholic acid.
The primary objective is to determine the effect of daily oral administration of elafibranor on serum alkaline phosphatase (ALP) in these patients, based on relative change versus placebo.
Secondary endpoints will include:
ALP < 1.67 × upper limit of normal (ULN) and total bilirubin within normal limit and > 15% decrease in ALP
Paris, Toronto, UK PBC scores
Pruritus and QoL (Quality of Life)
Safety of elafibranor in a PBC population
PBC is a rare disease with unmet need. Current treatments only cure a fraction of the patient population, and/or generate important side-effects such as pruritus, which is a major and well-known symptom already affecting most PBC patients.
Jean-François Mouney, Chairman & CEO of GENFIT, said: "As announced earlier this year, we are now in the process of launching a Phase 2 in PBC with our lead compound elafibranor. This strategic move is the result of the interactions we've had over the last year with key opinion leaders in PBC, who believe that PBC patients are still in need of alternative and appropriate treatments for their disease. The fact that the ALP-related surrogate endpoint has been clearly accepted by regulatory agencies as a valid endpoint for registration has been an important step, and a key element in our decision. We are encouraged by the literature on fibrates that seems to indicate a real potential for a PPARa like elafibranor to have a positive effect on ALP. We have designed a short trial, with only 3 months treatment, which means we should be able to readout on data in a relatively short timeframe."
Dr. Sophie Mégnien, Chief Medical Officer of GENFIT Corp., commented: "There is a real unmet need for many PBC patients who do not respond well enough to their UDCA treatment, i.e. do not reach the targeted level of serum alkaline phosphatase, and who - as such - remain at risk. We are pleased to be able today to take a step in a direction that represents a new hope for patients and a potentially safer alternative to currently available treatments. Based on its mechanism of action, we are confident in the potential of elafibranor to hit the appropriate target with a good level of efficacy, safety, and tolerability."
For more information:
Last updated on: 29/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.